Lab guide · Short peptides & copper complexes
What Is KPV? Alpha-MSH Fragment Peptide Research Overview
What is KPV? It is the tripeptide Lys-Pro-Val, the C-terminal fragment (residues 11-13) of alpha-melanocyte-stimulating hormone, studied in cell and mouse models of inflammation. This guide covers its structure, its origin in the melanocortin system, the PepT1 and NF-κB findings and the limits of the evidence.
Key takeaways
- KPV is Lys-Pro-Val, formula C16H30N4O4, molecular weight about 342.4 g/mol, the last three residues of the 13-residue hormone alpha-MSH.
- It lacks the His-Phe-Arg-Trp core that melanocortin receptors need for strong activation, so it is studied for inflammation rather than pigmentation.
- Dalmasso et al. (2008) reported that KPV enters intestinal and immune cells through the transporter PepT1 and inhibits NF-κB and MAP kinase signalling.
- Its evidence is preclinical (cells and mouse colitis models), and its mechanism is still debated.
What is KPV?
So, what is KPV? KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11-13 at the C-terminus of alpha-MSH, the 13-residue neuropeptide cut from pro-opiomelanocortin (POMC). The foundational study by Dalmasso et al. (2008) describes it as possessing anti-inflammatory properties whose mechanism of action was unknown at the time.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | H-Lys-Pro-Val-OH (KPV) |
| Length | 3 residues |
| Molecular formula | C16H30N4O4 |
| Molecular weight | 342.4 g/mol (average); 342.227 Da monoisotopic, calculated |
| CAS number | 67727-97-3 (supplier-listed) |
| Origin | alpha-MSH residues 11-13 |
I confirmed that the sequence reproduces the formula and mass. KPV has no methionine, cysteine or tryptophan, so it is among the simpler peptides to handle. A tripeptide of this size is small enough that mass spectrometry cannot distinguish it from isomers such as Lys-Val-Pro, so identity also depends on sequencing or chromatography against a reference.
Discovery and research history
The anti-inflammatory activity of alpha-MSH was traced to its C-terminal end. The tripeptide KPV was then tested as the smallest active fragment. Two 2008 papers reported anti-inflammatory activity in colitis models: Dalmasso et al. (2008) in Gastroenterology and a study of KPV in murine models of inflammatory bowel disease in Inflammatory Bowel Diseases.
A 2026 FDA briefing document for the Pharmacy Compounding Advisory Committee reviews the KPV literature, showing the compound has drawn regulatory attention as well as research interest (FDA).
Mechanism: PepT1 uptake and NF-κB inhibition
Transport into cells
Dalmasso et al. found that KPV is transported into cells by PepT1, a di- and tripeptide transporter normally expressed in the small intestine and induced in the colon during inflammatory bowel disease. At nanomolar concentrations KPV inhibited activation of NF-κB and MAP kinase signalling and reduced secretion of pro-inflammatory cytokines (PubMed).
An open mechanistic question
Some studies suggest MC1R involvement in other cell types, but in intestinal epithelium the effect has been shown to depend on PepT1 transport, a route that does not need a melanocortin receptor. KPV lacks the His-Phe-Arg-Trp core that melanocortin receptors use, so the mechanism remains an open question.
Main research areas
- NF-κB and cytokine signalling: reduced activation and cytokine release in cultured cells.
- Intestinal inflammation models: DSS- and TNBS-induced colitis in mice.
- Skin and keratinocyte models: α-MSH-derived fragments in dermal inflammation studies.
- Melanocortin pharmacology: separating the anti-inflammatory activity of α-MSH from its pigmentary activity.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula and mass are straightforward and verifiable. |
| Cell studies | PepT1-dependent uptake and inhibition of NF-κB and MAPK signalling at nanomolar concentrations. |
| Animal studies | Reduced incidence of colitis indices in DSS- and TNBS-induced mouse models, with lower pro-inflammatory cytokine expression. |
| Human research | No completed registered clinical trials were found in the sources reviewed. |
Two mouse models of chemically induced colitis are a limited basis. They show an effect in those models, not in disease generally.
Scientific limitations and open questions
- The evidence is preclinical, from cell lines and two mouse colitis models.
- The mechanism is debated, with PepT1 and possible melanocortin-receptor routes both proposed.
- A tripeptide has a short half-life and is likely to be degraded rapidly outside cells, which complicates interpretation.
- Independent replication beyond the early 2008 papers is limited in the sources reviewed.
Analytical and laboratory considerations
Mass spectrometry should show the intact tripeptide at about 342.4 Da, and HPLC should separate sequence isomers and truncated products. Because KPV is short, hydrophilic and basic, it elutes early in reverse-phase methods and needs a suitable gradient or ion-pairing agent.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the KPV product page.
Sources and further reading
- Dalmasso G. et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 134(1):166-178. PubMed · PMC full text
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 14(3):324-331 (2008). PubMed
- FDA briefing document, Pharmacy Compounding Advisory Committee (2026). FDA
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is KPV?
What is the molecular weight and formula of KPV?
Does KPV act on melanocortin receptors like alpha-MSH?
What is PepT1 and why does it matter for KPV?
What did the 2008 colitis studies show?
Is there human clinical evidence for KPV?
Does KPV cause pigmentation?
Keep reading
Related reading
KPV
Current batches, formats and the COA for KPV.
What is Melanotan II?
A full cyclic melanocortin agonist, for contrast with KPV.
Peptide blends explained
Why component research does not define a combined formulation.
Research-grade KPV, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
